Edition:
United States

China Pharma Holdings Inc (CPHI.A)

CPHI.A on American Stock Exchange

0.26USD
17 Feb 2017
Change (% chg)

$-0.01 (-3.70%)
Prev Close
$0.27
Open
$0.26
Day's High
$0.27
Day's Low
$0.26
Volume
1,455
Avg. Vol
8,838
52-wk High
$0.35
52-wk Low
$0.13

CPHI.A

Chart for CPHI.A

About

China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and... (more)
No analyst recommendations are available for CPHI.A.

Overall

Beta: 2.45
Market Cap(Mil.): $11.33
Shares Outstanding(Mil.): 43.58
Dividend: --
Yield (%): --

Financials

  CPHI.A Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -0.28 -- --
ROI: -14.35 -4.08 13.06
ROE: -16.49 4.84 14.19

BRIEF-North China Pharma's chairman resigns due to personal reasons

* Says its Chairman Guo Zhouke resigns due to personal reasons

Feb 09 2017

Fitch: China Pharma Manufacturers: Healthy Growth as Generics Dominate

(The following statement was released by the rating agency) SHANGHAI, November 23 (Fitch) Fitch Ratings expects China's pharmaceutical sales through hospitals and retail pharmacies to maintain a healthy growth over the medium term. This momentum is underpinned by rising medical demand from an ageing population; continuing urbanisation; rising disposable income; broadening medical insurance coverage; and improving public access to medical treatment and facilities. However, our growth outloo

Nov 23 2016

Fitch: Margin Pressure and Consolidation for China's Pharma Distributors

(The following statement was released by the rating agency) Link to Fitch Ratings' Report: China Pharmaceutical Distributors and Retail Pharmacies Blue Book https://www.fitchratings.com/site/re/888932 SHANGHAI, November 23 (Fitch) Intensifying competition, stricter regulations and declining drug prices will pressure the margins of Chinese pharmaceutical distributors, while rising labour and rental costs will constrain retail pharmacy profitability, leading to further consolidation of the hig

Nov 23 2016

BRIEF-North China Pharma plans to issue debt financing instruments

* Says it plans to issue up to 2.0 billion yuan ($290.00 million) debt financing instruments

Nov 23 2016

BRIEF-China Pharma Holdings reports Q3 loss per share $0.04

* China Pharma Holdings reports third quarter financial results

Nov 15 2016

More From Around the Web

Competitors

Earnings vs. Estimates